Published in J Immunol on March 15, 2001
Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol (2013) 5.43
Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts. Cancer Res (2010) 2.13
Modeling the early stages of vascular network assembly. EMBO J (2003) 1.78
Interleukin-19 increases angiogenesis in ischemic hind limbs by direct effects on both endothelial cells and macrophage polarization. J Mol Cell Cardiol (2014) 1.48
Activation of natural killer (NK) T cells during murine cytomegalovirus infection enhances the antiviral response mediated by NK cells. J Virol (2003) 1.35
Colitis-associated cancer: the role of T cells in tumor development. Semin Immunopathol (2009) 1.19
Mechanism of IL-12 mediated alterations in tumour blood vessel morphology: analysis using whole-tissue mounts. Br J Cancer (2003) 1.07
Immune cells and angiogenesis. J Cell Mol Med (2009) 0.96
Harnessing the antitumor potential of macrophages for cancer immunotherapy. Oncoimmunology (2013) 0.93
Mouse tumor vasculature expresses NKG2D ligands and can be targeted by chimeric NKG2D-modified T cells. J Immunol (2013) 0.92
RAS interaction with PI3K p110α is required for tumor-induced angiogenesis. J Clin Invest (2014) 0.87
Jack of all trades: pleiotropy and the application of chemically modified tetracycline-3 in sepsis and the acute respiratory distress syndrome (ARDS). Pharmacol Res (2011) 0.85
The immunocytokine NHS-IL12 as a potential cancer therapeutic. Oncotarget (2014) 0.83
The Glycogen Synthase Kinase 3α and β Isoforms Differentially Regulates Interleukin-12p40 Expression in Endothelial Cells Stimulated with Peptidoglycan from Staphylococcus aureus. PLoS One (2015) 0.79
Focused ultrasound-induced blood-brain barrier opening to enhance interleukin-12 delivery for brain tumor immunotherapy: a preclinical feasibility study. J Transl Med (2015) 0.79
Irradiation-induced up-regulation of HLA-E on macrovascular endothelial cells confers protection against killing by activated natural killer cells. PLoS One (2010) 0.78
Accelerated wound healing phenotype in Interleukin 12/23 deficient mice. J Inflamm (Lond) (2011) 0.78
The innate immune system recognizes and regulates major histocompatibility complex class I (MHCI) expression on MHCIlow tumor cells. Cancer Immun (2008) 0.77
Peripheral Inflammation, Apolipoprotein E4, and Amyloid-β Interact to Induce Cognitive and Cerebrovascular Dysfunction. ASN Neuro (2017) 0.76
Trends in cancer immunotherapy. Clin Med Insights Oncol (2010) 0.75
Interleukin-12 inhibits pathological neovascularization in mouse model of oxygen-induced retinopathy. Sci Rep (2016) 0.75
In Ovo Administration of Silver Nanoparticles and/or Amino Acids Influence Metabolism and Immune Gene Expression in Chicken Embryos. Int J Mol Sci (2015) 0.75
A novel transforming protein (SHC) with an SH2 domain is implicated in mitogenic signal transduction. Cell (1992) 6.86
Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences. Nat Genet (2000) 6.12
Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. Immunity (1997) 4.19
Cytokine regulation of endothelial cell function. FASEB J (1992) 3.00
International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia (2007) 2.96
Role of alphavbeta3 integrin in the activation of vascular endothelial growth factor receptor-2. EMBO J (1999) 2.92
The intriguing role of polymorphonuclear neutrophils in antitumor reactions. Blood (2001) 2.92
DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice. J Immunol (2000) 2.65
The release of platelet-activating factor from human endothelial cells in culture. J Immunol (1983) 2.41
Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J Exp Med (1996) 2.32
Antitumor vaccination: where we stand. Haematologica (2000) 2.30
Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood (1999) 2.28
Lifestyle intervention by group care prevents deterioration of Type II diabetes: a 4-year randomized controlled clinical trial. Diabetologia (2002) 2.23
Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2/neu transgenic mice. J Exp Med (1998) 2.08
Six-minute walking performance in patients with moderate-to-severe heart failure; is it a useful indicator in clinical practice? Eur Heart J (2001) 2.07
Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients. Ann Oncol (2006) 1.95
Tumor necrosis factor/cachectin stimulates peritoneal macrophages, polymorphonuclear neutrophils, and vascular endothelial cells to synthesize and release platelet-activating factor. J Exp Med (1987) 1.95
Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia. Blood (2001) 1.79
Progressive growth in immunodeficient mice and host cell recruitment by mouse endothelial cells transformed by polyoma middle-sized T antigen: implications for the pathogenesis of opportunistic vascular tumors. Proc Natl Acad Sci U S A (1994) 1.78
Agonistic monoclonal antibodies against the Met receptor dissect the biological responses to HGF. J Cell Sci (1998) 1.75
The angiogenesis induced by HIV-1 tat protein is mediated by the Flk-1/KDR receptor on vascular endothelial cells. Nat Med (1996) 1.72
Myocardial scarring by delayed enhancement cardiovascular magnetic resonance in thalassaemia major. Heart (2009) 1.71
Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic mice. J Exp Med (2001) 1.66
Release of platelet-activating factor (PAF) and histamine. II. The cellular origin of human PAF: monocytes, polymorphonuclear neutrophils and basophils. Immunology (1981) 1.62
Heat shock protein 70 induced during tumor cell killing induces Th1 cytokines and targets immature dendritic cell precursors to enhance antigen uptake. J Immunol (1999) 1.60
Interleukin 1 stimulates platelet-activating factor production in cultured human endothelial cells. J Clin Invest (1986) 1.57
The molecular action of tumor necrosis factor-alpha. Eur J Biochem (1991) 1.52
c-fos-induced growth factor/vascular endothelial growth factor D induces angiogenesis in vivo and in vitro. Proc Natl Acad Sci U S A (1999) 1.49
HOXB7: a key factor for tumor-associated angiogenic switch. Cancer Res (2001) 1.47
The tumor-suppressor gene FHIT is involved in the regulation of apoptosis and in cell cycle control. Proc Natl Acad Sci U S A (1999) 1.47
Expression of cytokine/growth factors and their receptors in human melanoma and melanocytes. Int J Cancer (1994) 1.44
Cytokine regulation of endothelial cell function: from molecular level to the bedside. Immunol Today (1997) 1.43
Establishment and characterization of a human neuroblastoma cell line. Int J Cancer (1989) 1.43
Regression of an established tumor genetically modified to release granulocyte colony-stimulating factor requires granulocyte-T cell cooperation and T cell-produced interferon gamma. J Exp Med (1993) 1.43
An international comparison of knowledge levels of medical students: the Maastricht Progress Test. Med Educ (1996) 1.42
Concomitant factors of decompensation in chronic heart failure. Am J Cardiol (1996) 1.42
Interferon-gamma receptor 2 expression as the deciding factor in human T, B, and myeloid cell proliferation or death. J Leukoc Biol (2001) 1.39
Local cytokine availability elicits tumor rejection and systemic immunity through granulocyte-T-lymphocyte cross-talk. Cancer Res (1992) 1.39
Incidence and prevalence rate estimation of GH treatment exposure in Piedmont pediatric population in the years 2002-2004: Data from the GH Registry. J Endocrinol Invest (2006) 1.39
Analysis of mammary carcinoma onset and progression in HER-2/neu oncogene transgenic mice reveals a lobular origin. Lab Invest (1999) 1.37
HOXB7 constitutively activates basic fibroblast growth factor in melanomas. Mol Cell Biol (1996) 1.35
Tumor necrosis factor-alpha regulates expression of vascular endothelial growth factor receptor-2 and of its co-receptor neuropilin-1 in human vascular endothelial cells. J Biol Chem (1998) 1.35
Percolation, morphogenesis, and burgers dynamics in blood vessels formation. Phys Rev Lett (2003) 1.33
Expression of transcripts for two interleukin 8 receptors in human phagocytes, lymphocytes and melanoma cells. Biochem J (1993) 1.32
Constitutive expression of lymphoma-associated NFKB-2/Lyt-10 proteins is tumorigenic in murine fibroblasts. Oncogene (1997) 1.31
Inhibition of interferon-gamma may suppress allograft reactivity by T lymphocytes in vitro and in vivo. Science (1985) 1.30
Distribution of interferon-gamma receptor in human tissues. Eur J Immunol (1992) 1.30
Antitumor efficacy of adenocarcinoma cells engineered to produce interleukin 12 (IL-12) or other cytokines compared with exogenous IL-12. J Natl Cancer Inst (1997) 1.30
PAF/cytokine auto-generated feedback networks in microvascular immune injury: consequences in shock, ischemia and graft rejection. J Lipid Mediat (1992) 1.29
Cytokine gene transfer in tumor inhibition and tumor therapy: where are we now? Immunol Today (1994) 1.29
The role of the macrophage as the stimulator cell in contact sensitivity. J Immunol (1977) 1.28
Mediators of immune-complex-induced aggregation of polymorphonuclear neutrophils. II. Platelet-activating factor as the effector substance of immune-induced aggregation. Int Arch Allergy Appl Immunol (1981) 1.27
Maternal vascular prostacyclin activity in pre-eclampsia. Lancet (1980) 1.24
Expression of beta 1B integrin isoform in CHO cells results in a dominant negative effect on cell adhesion and motility. J Cell Biol (1994) 1.24
Naturally occurring anti-band-3 antibodies and complement together mediate phagocytosis of oxidatively stressed human erythrocytes. Proc Natl Acad Sci U S A (1987) 1.23
A flow cytometry assay simultaneously detects independent apoptotic parameters. Cytometry (2001) 1.22
Natural cell-mediated cytotoxicity against Trichomonas vaginalis in the mouse. I. Tissue, strain, age distribution, and some characteristics of the effector cells. J Immunol (1980) 1.18
Bone marrow stroma in humans: anti-nerve growth factor receptor antibodies selectively stain reticular cells in vivo and in vitro. Blood (1993) 1.18
HIV-tat protein is a heparin-binding angiogenic growth factor. Oncogene (1996) 1.18
Vascular endothelial growth factor-C stimulates the migration and proliferation of Kaposi's sarcoma cells. J Biol Chem (1999) 1.18
Tumor necrosis factor alpha-induced angiogenesis depends on in situ platelet-activating factor biosynthesis. J Exp Med (1994) 1.17
Sleep abnormalities in type 2 diabetes may be associated with glycemic control. Acta Diabetol (2008) 1.16
Transduction of the SkBr3 breast carcinoma cell line with the HOXB7 gene induces bFGF expression, increases cell proliferation and reduces growth factor dependence. Oncogene (1998) 1.16
Alkyl-ether phosphoglycerides influence calcium fluxes into human endothelial cells. J Immunol (1985) 1.16
Obligatory role of IFN-gamma in induction of lymphokine-activated and T lymphocyte killer activity, but not in boosting of natural cytotoxicity. J Immunol (1988) 1.15
Role of neutrophils and CD4+ T lymphocytes in the primary and memory response to nonimmunogenic murine mammary adenocarcinoma made immunogenic by IL-2 gene. J Immunol (1992) 1.15
Temporary regression of recurrent squamous cell carcinoma of the head and neck is achieved with a low but not with a high dose of recombinant interleukin 2 injected perilymphatically. Br J Cancer (1994) 1.15
Inhibition of tumor growth and enhancement of metastasis after transfection of the gamma-interferon gene. Int J Cancer (1993) 1.15
Expression of adhesion molecules, platelet-activating factor, and chemokines by Kaposi's sarcoma cells. J Immunol (1994) 1.15
p185(neu) protein is required for tumor and anchorage-independent growth, not for cell proliferation of transgenic mammary carcinoma. Int J Cancer (2000) 1.14
Immune events associated with the cure of established tumors and spontaneous metastases by local and systemic interleukin 12. Cancer Res (1999) 1.14
Expression of an exogenous interleukin 6 gene in human Epstein Barr virus B cells confers growth advantage and in vivo tumorigenicity. J Exp Med (1990) 1.14
Gene transfer in dendritic cells, induced by oral DNA vaccination with Salmonella typhimurium, results in protective immunity against a murine fibrosarcoma. Blood (1998) 1.13
Lymphokine-activated tumor inhibition in vivo. I. The local administration of interleukin 2 triggers nonreactive lymphocytes from tumor-bearing mice to inhibit tumor growth. J Immunol (1985) 1.11
A comparison of the alcohol-attributable mortality in four European countries. Eur J Epidemiol (2003) 1.11
CD4 T cells inhibit in vivo the CD8-mediated immune response against murine colon carcinoma cells transduced with interleukin-12 genes. Eur J Immunol (1995) 1.11
Free cytoplasmic Ca++ at rest and after cholinergic stimulus is increased in cultured muscle cells from Duchenne muscular dystrophy patients. Neurology (1988) 1.10
Neutrophils in the antitumoral immune response. Chem Immunol Allergy (2003) 1.09
Immunoprevention of cancer: is the time ripe? Cancer Res (2000) 1.09
Heterologous sera: a target for in vitro cell-mediated cytotoxicity. J Immunol (1976) 1.09
Src-mediated activation of alpha-diacylglycerol kinase is required for hepatocyte growth factor-induced cell motility. EMBO J (2000) 1.09